Remdesivir, an experimental antiviral drug from Gilead Sciences, led to faster recovery of patients with advanced COVID-19, the disease caused by the new coronavirus, according to data from a randomized clinical trial released April 29 by the National Institutes of Allergy and Infectious Diseases.
Speaking at a White House briefing, NIAID director Dr. Anthony Fauci said that the data "show that remdesivir has a clear-cut, significant positive effect in diminishing the time to recovery." He added